Peer Review History

Original SubmissionJune 3, 2022
Decision Letter - Fabio Sallustio, Editor

PONE-D-22-16135miR-20a is upregulated in serum from domestic feline with PKD1 mutationPLOS ONE

Dear Dr. Paludo,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

In addition to extensively address the points raised by the reviewer 1, please include more details in the Methods. For example, the info about what primer/assays have been used for the miRNA detection is missing and it is mandatory. Moreover, please include graph of real-time miRNA expression results in the paper and not as supplemental file. In the graph  of miRNA expression results how the fold change has been calculated? Respect to what? It is not clear. Please, specify this also in Methods, in addition to the text and figure legends.

Please submit your revised manuscript by Nov 16 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Fabio Sallustio, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. In the ethics statement in the Methods and online submission information, please specify whether cat owners' consent was obtained and (2) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If the need for consent was waived by the ethics committee, please include this information

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Comments to the Author

microRNAs (miRs) are the most thoroughly studied none coding RNA. miRs could be of important role in regulating genes expression which may affect disease progression, or as a diagnostic and prognostic biomarker of different diseases. miRs are widely studied in many kinds of diseases, such as ADPKD in human and in mice. But the studies of miRs in cats with ADPKD are scarce. In the present study, detection of serum and plasma levels of 5 miRs were performed in ADPKD cats, as well as in control ones. The results showed that serum miR-20a was upregulated and could be a potential biomarker in ADPKD cats. The detection of miRs of serum samples had a high quality than that of plasma. The results may be of value in the studies of ADPDK in cats. However, there some question needs to be clarified.

1.The 5 miRs selected in this study based on a previous study of miRs of kidney specimens from ADPKD cats, detailed description of these 5 miRs association with ADPKD were absent and needs to be added.

2.The role of miR-20a on cystic formation in ADPKD cats was inferred by the author. However, the relation between serum levels of miR-20a and renal cysts formation or different disease stages were absent.

3.The bioinformatics of miR-20a and its target genes have not been fully discussed.

4.As none coding RNAs is species and genus specific, the deduction (line 37-38) “better understanding of relative expression profiles will further enhance the development of novel diagnostic and prognostic biomarkers as well as prompting patient management” is inappropriate.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Liangzhong Sun

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

1. Comments: “the info about what primer/assays have been used for the miRNA detection is missing and it is mandatory.”

Answer: In Materials and methods, Table 1 was added with the complete information about the primer/assays used in the study.

2. Comments: “please include graph of real-time miRNA expression results in the paper and not as supplemental file.”

Answer: In Materials and methods, Fig 1 and Fig 2 were added.

3. Comments: “In the graph of miRNA expression results how the fold change has been calculated? Respect to what? It is not clear.”

Answer: In Materials and methods, the complete information about how the fold change was calculated is added in lines 155 – 169 on manuscript with track changes document.

4. Comments: “If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results.”

Answer: All protocols were deposited to Protocols.io, and are provided as supplemental files.

5. Comments: “In the ethics statement in the Methods and online submission information, please specify whether cat owners' consent was obtained and (2) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If the need for consent was waived by the ethics committee, please include this information”

Answer: In Materials and methods, the information about the consent form was added, and a copy with the text (in Portuguese and English) is provided as a supplemental file.

6. Comments: “The 5 miRs selected in this study based on a previous study of miRs of kidney specimens from ADPKD cats, detailed description of these 5 miRs association with ADPKD were absent and needs to be added.”

Answer: In lines 70 – 90 of Introduction, the detailed descriptions of the 5 miRs and its association with ADPK were added.

7. Comments: “The role of miR-20a on cystic formation in ADPKD cats was inferred by the author. However, the relation between serum levels of miR-20a and renal cysts formation or different disease stages were absent.”

Answer: In Results and discussion, the information about miR-20a serum levels and renal cysts formation was added in lines 230 – 235 on manuscript with track changes document.

8. Comments: “The bioinformatics of miR-20a and its target genes have not been fully discussed.”

Answer: In Results and discussion, the bioinformatics of miR-20a and its target genes was added in lines 244 – 249 on manuscript with track changes document.

9. Comments: “As none coding RNAs is species and genus specific, the deduction (line 37-38) “better understanding of relative expression profiles will further enhance the development of novel diagnostic and prognostic biomarkers as well as prompting patient management” is inappropriate.”

Answer: In Abstract, the sentence was removed.

10. Comments: “While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/.”

Answer: All figures were uploaded to PACE.

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Fabio Sallustio, Editor

miR-20a is upregulated in serum from domestic feline with PKD1 mutation

PONE-D-22-16135R1

Dear Dr. Paludo,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Fabio Sallustio, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors have addressed our concerns and made the manuscript acceptable for publication. In Materials and methods, the information about the consent form was added,If applicable, we recommend that you submit the ethics Ethical review proof as well as.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

**********

Formally Accepted
Acceptance Letter - Fabio Sallustio, Editor

PONE-D-22-16135R1

miR-20a is upregulated in serum from domestic feline with PKD1 mutation

Dear Dr. Paludo:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Fabio Sallustio

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .